Coreline Soft is intensifying its global expansion by entering the Australian market, following successful projects in European countries. On the 2nd, the company announced the supply of its AI-powered software ‘AVIEW LCS Plus’—which detects lung nodules, emphysema, and coronary artery calcification—to Nepean Diagnostics, a leading radiology center in Australia.
This contract marks Coreline Soft’s first entry into the Australian market. It is particularly significant as it comes ahead of the country’s rollout of the National Lung Cancer Screening Program (NLCSP). The Nepean Diagnostics center, located in New South Wales, is a major private radiology provider and is among the first to voluntarily adopt AI technology ahead of the national screening initiative.
Coreline Soft has previously achieved notable success in Australia through a strategic partnership with Paragon Care, one of the country’s leading healthcare companies with an annual revenue of approximately 3 trillion KRW. Paragon Care supplies over 100 brands of diagnostic and therapeutic equipment and solutions. The two companies have jointly promoted their offerings at prominent conferences, including the Australian Lung Cancer Conference (ALCC 2025), garnering strong interest from local medical professionals. As the NLCSP approaches its implementation date, inquiries from radiology centers and radiologists across Australia regarding AI solutions have surged, leading to this recent achievement.
AVIEW LCS Plus utilizes low-dose CT (computed tomography) scans to automatically detect lung nodules, quantify emphysema, and analyze coronary artery calcification with a single scan. Coreline Soft’s technology has been validated in major European projects, such as ‘4ITLR’ in Europe, ‘EDIN’ in the United Kingdom, ‘RISP’ in Italy, and ‘HANSE’ in Germany, demonstrating its reliability and stability on the international stage.
The Australian government initiated a pilot lung cancer screening assessment in 2019 and officially announced the program in 2023. From July 1st, the NLCSP is being officially implemented nationwide. The contract with Coreline Soft is a strategic move to secure early validation data and build trust among local healthcare professionals. The company plans to expand step-by-step across major radiology centers throughout Australia.
Kim Jin-guk, CEO of Coreline Soft, stated, “Introducing AVIEW LCS Plus just before the national implementation of NLCSP is more than just technology transfer; it’s a move to lead the country’s screening network strategy.” He added, “Leveraging a platform repeatedly proven in various national projects, alongside our partnership with Paragon Care, we aim to accelerate the adoption of our solution across Australia.”
Globally, countries in Europe are advancing their efforts to combat lung cancer, the leading cause of cancer-related death. Many countries, such as Germany, are implementing government-led regular screening programs and increasingly recommending AI solutions after pilot projects. Coreline Soft also launched a dedicated promotional webpage for Australian hospitals and radiologists on July 1st. The page details the technological features, case studies, and clinical guidelines for AVIEW LCS Plus, facilitating immediate evaluation by local medical professionals regarding solution adoption.
